Profile of the B cell receptor repertoire and antibody responses upon 17DD-YF vaccine boosting
Christina A. MartinsiD, Milene Barbosa CarvalhoiD, João Henrique Diniz Brandão GervásioiD, Carlena Navas, Luciana W. ZuccheratoiD, Marcele Neves RochaiD, Manuela FerreiraiD, Camila Dutra de SouzaiD, Adriana de Souza Azevedo Soares, Brenda de Moura DiasiD, Nathalia dos Santos AlvesiD, Sheila Maria Barbosa de LimaiD, Waleska Dias SchwarcziD, Andréa Marques Vieira da SilvaiD, Ana Paula Dinis Ano BomiD, Camilla Bayma Fernandes, Renata Carvalho Pereira, Mauro Martins TeixeiraiD, Jason J. LavinderiD, Gregory C. IppolitoiD, Liza Figueiredo FelicoriiD
Abstract
Although the 17DD-YF vaccine is highly effective in conferring long-term immunity, recent studies suggest that booster doses may be necessary in endemic areas. In this study, we characterized the dynamics of the B cell repertoire following 17DD-YF booster vaccination and examined its impact on antibody kinetics. Using a combined approach of serological analysis and B cell receptor (BCR) sequencing, we investigated molecular features of the antibody response in four vaccinated individuals from a YFV-endemic region. Our results indicate that the booster induces a transient antibody response, with limited effect on the neutralization capacity against DENV1-4 and ZIKV. Notably, we observed a rapid clonal expansion of B cells within 14 days post-vaccination, predominantly involving IgA and IgG isotypes. However, this expansion was short-lived, with reduced magnitude and persistence of these lineages by day 28. Interestingly, some of the expanded lineages shared sequence similarity with previously characterized anti-DENV and anti-ZIKV antibodies, although further validation is required to assess their functional relevance and presence in circulating serum. Together, these findings highlight the transient nature and isotype composition of the antibody response following YFV revaccination and provide insights into the complex interplay between pre-existing immunity and recall responses in individuals living in endemic regions.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Live attenuated YFV-17D vaccine induces robust B and T cell immunity in vaccine-draining lymph nodes
Rachel B Evans, Wen Shi Lee, … Adam K Wheatley·bioRxiv·Nov 5, 2026
- Longitudinal Profiling of CD4⁺ T Cell Responses Following de novo Yellow Fever Vaccination
Dzenis Gojak, Maria S. Kuznetsova, … Benson Ogunjimi·bioRxiv·Feb 28, 2026
- Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus
J. E. Crowe, M. Doyle, … M. Diamond·bioRxiv·Feb 28, 2022
- Prior flavivirus immunity skews the yellow fever vaccine response to expand cross-reactive antibodies with increased risk of antibody dependent enhancement of Zika and dengue virus infection
A. Santos-Peral, F. Luppa, … S. Rothenfusser·bioRxiv·May 7, 2023
- Vaccination reshapes the virus-specific T cell repertoire in unexposed adults
Y.-G. Pan, B. Aiamkitsumrit, … L. F. Su·bioRxiv·Oct 1, 2020
- Pre-existing YFV-17D immunity mediates T cell cross-protection against DENV-2 infection
Prince Baffour Tonto, Sebastian Gallon, … Bobby Brooke Herrera·bioRxiv·Apr 16, 2025